290304-24-4
290304-24-4 結構式
基本信息
DAUN 02
DAUN-02
5,12-Naphthacenedione, 8-acetyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-[[2,3,6-trideoxy-3-[[[[4-(β-D-galactopyranosyloxy)-3-nitrophenyl]methoxy]carbonyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)-
(8S,10S)-8-Acetyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-[[2,3,6-trideoxy-3-[[[[4-(beta-D-galactopyranosyloxy)-3-nitrophenyl]methoxy]carbonyl]amino]-alpha-L-lyxo-hexopyranosyl]oxy]-5,12-naphthacenedione
物理化學性質
常見問題列表
|
Topoisomerase
|
Daunorubicins/Doxorubicins
|
Daun02 is a prodrug, which is converted by β-galactosidase to Daunorubicin, which has been shown to reduce calcium ion (Ca 2+ )-dependent action potentials in neuroblastoma cells. Daunorubicin is a topoisomerase inhibitor. Daun02 is a good substrate for β-galactosidase (β-gal). The concentration of Daun02 producing 50% (EC 50 ) decrease in cell viability is 0.5 μM, 1.5 μM, and 3.5 μM for T47-D, Panc02, and MCF-7, respectively.
Daun02 is a good substrate for β-gal with K m and V max values of 0.37 mM and 8.6 μmol/min/mg protein. At a concentration of 10 -5 M, Daun02 is 79% bound to plasma protein compares to 94% for Daunomycin.